Ceratose actínica

Referências

Principais artigos

Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006 May;55(5):suppl 1-8. Resumo

Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg. 1997 Nov;23(11):1009-19. Resumo

de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017 Jan;176(1):20-43. Resumo

Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct;131(4):455-64. Resumo

Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002 Jul;20(3):373-85. Resumo

Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004415.Texto completo  Resumo

Artigos de referência

1. Moy R. Clinical presentation of actinic keratosis and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10. Resumo

2. Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006 May;55(5):suppl 1-8. Resumo

3. Hawrot A, Alam M, Ratner D. Squamous cell carcinoma. Curr Probl Dermatol. 2003 May 1;15(3):91-133.

4. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg. 1997 Nov;23(11):1009-19. Resumo

5. Kuflik AS, Schwartz RA. Actinic keratosis and squamous cell carcinoma. Am Fam Physician. 1994 Mar;49(4):817-20. Resumo

6. Chung HJ, McGuigan KL, Osley KL, et al. Pigmented solar (actinic) keratosis: an underrecognized collision lesion. J Am Acad Dermatol. 2013 Apr;68(4):647-53. Resumo

7. Yu RC, Pryce DW, Macfarlane AW, et al. A histopathological study of 643 cutaneous horns. Br J Dermatol. 1991 May;124(5):449-52 Resumo

8. Schosser RH, Hodge SJ, Gaba CR, et al. Cutaneous horns: a histopathologic study. South Med J. 1979 Sep;72(9):1129-31. Resumo

9. Hemminki K, Zhang H, Czene K. Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol. 2003 Jul;139(7):885-9.Texto completo  Resumo

10. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002 Apr;146 Suppl 61:1-6. Resumo

11. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005 Aug 10;294(6):681-90.Texto completo  Resumo

12. de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017 Jan;176(1):20-43. Resumo

13. Anwar J, Wrone DA, Kimyai-Asadi A, et al. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004 May-Jun;22(3):189-96. Resumo

14. Helfand M, Gorman AK, Mahon S, et al; US Department of Health and Human Services. Actinic keratoses: final report. May 2001 [internet publication].Texto completo

15. Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol. 1995 Apr;32(4):653-8. Resumo

16. Lehmann AR, Bridges BA. Sunlight-induced cancer: some new aspects and implications of the xeroderma pigmentosum model. Br J Dermatol. 1990 Apr;122 Suppl 35:115-9. Resumo

17. Lambert WC, Kuo HR, Lambert MW. Xeroderma pigmentosum. Dermatol Clin. 1995 Jan;13(1):169-209. Resumo

18. Luande J, Henschke CI, Mohammed N. The Tanzanian human albino skin. Natural history. Cancer. 1985 Apr 15;55(8):1823-8. Resumo

19. Memon AA, Tomenson JA, Bothwell J. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000 Jun;142(6):1154-9. Resumo

20. Zagula-Mally ZW, Rosenberg EW, Kashgarian M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer. 1974 Aug;34(2):345-9. Resumo

21. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol. 2000 Aug;115(2):273-7.Texto completo  Resumo

22. Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol. 1988 Dec;19(6):1045-52. Resumo

23. Cooper KD, Fox P, Neises G, et al. Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of Langerhans cell-dependent function is followed by the appearance of T6- Dr+ cells that enhance epidermal alloantigen presentation. J Immunol. 1985 Jan;134(1):129-37. Resumo

24. Granstein RD, Askari M, Whitaker D, et al. Epidermal cells in activation of suppressor lymphocytes: further characterization. J Immunol. 1987;138:4055-4062. Resumo

25. Winkelmann, Baldes EJ, Zollman PE. Squamous cell tumors induced in hairless mice with ultraviolet light. J Invest Dermatol. 1960 Feb;34:131-8. Resumo

26. Nomura T, Nakajima H, Hongyo T, et al. Induction of cancer, actinic keratosis, and specific p53 mutations by UVB light in human skin maintained in severe combined immunodeficient mice. Cancer Res. 1997 Jun 1;57(11):2081-4.Texto completo  Resumo

27. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453-6. Resumo

28. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol. 2003 Jan;139(1):66-70. Resumo

29. Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. Cutis. 2011 Jul;88(1):suppl 1-8. Resumo

30. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523-6. Resumo

31. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15-6. Resumo

32. Satchell AC, Barnetson RS, Halliday GM. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. Br J Dermatol. 2004 Jul;151(1):42-9. Resumo

33. Clifford JL, Walch E, Yang X, et al. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002 Jul;8(7):2067-72.Texto completo  Resumo

34. Yaar M, Karassik RL, Schnipper LE, et al. Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol. 1985 Jul;85(1):70-4. Resumo

35. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7673-8.Texto completo  Resumo

36. Smit NP, Vink AA, Kolb RM, et al. Melanin offers protection against induction of cyclobutane pyrimidine dimers and 6-4 photoproducts by UVB in cultured human melanocytes. Photochem Photobiol. 2001 Sep;74(3):424-30. Resumo

37. Ortonne JP. Photoprotective properties of skin melanin. Br J Dermatol. 2002 Apr;146 Suppl 61:7-10. Resumo

38. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct;131(4):455-64. Resumo

39. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J (Clin Res Ed). 1988 Jan 2;296(6614):13-7.Texto completo  Resumo

40. Marks R, Jolley D, Lectsas S, Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust. 1990 Jan 15;152(2):62-6. Resumo

41. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7. Resumo

42. Stockfleth E, Ulrich C, Meyer T, et al. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251-8. Resumo

43. Ulrich C, Schmook T, Sachse MM, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7. Resumo

44. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993 Oct 14;329(16):1147-51. Resumo

45. Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995 Feb;131(2):170-5. Resumo

46. Rigel DS. Photoprotection: a 21st century perspective. Br J Dermatol. 2002 Apr;146 Suppl 61:34-7. Resumo

47. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994 May 5;330(18):1272-5. Resumo

48. Zalaudek I, Giacomel J, Argenziano G, et al. Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol. 2006 Nov;155(5):951-6. Resumo

49. Zalaudek I, Giacomel J, Schmid K, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: A progression model. J Am Acad Dermatol. 2012 Apr;66(4):589-97. Resumo

50. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006 Jul-Aug;16(4):335-9. Resumo

51. Elder DE, Elenitsas R, Johnson Jr. BL, et al. Lever's histopathology of the skin. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.

52. Stolz W, Braun-Falco O, Bilek P, et al. Color atlas of dermatoscopy. 1st ed. London, UK: Blackwell Science Ltd; 1994.

53. Menzies SW, Crotty KA, Ingvar C, et al. An atlas of surface microscopy of pigmented skin lesions. 1st ed. Sydney, Australia: McGraw-Hill Book Company Australia Pty Limited; 1996.

54. Donnelly AM, Halbert AR, Rohr JB. Discoid lupus erythematosus. Australas J Dermatol. 1995 Feb;36(1):3-10; quiz 11-2. Resumo

55. Weber F, Fritsch P. Clinical differential diagnosis of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzica T, eds. Cutaneous lupus erythematosus. Berlin: Springer-Verlag; 2005.

56. Kontos AP, Jirsari M, Jacobsen G, et al. Immunoglobulin M predominance in cutaneous lupus erythematosus. J Cutan Pathol. 2005 May;32(5):352-5. Resumo

57. Zedek DC, Smith ET Jr, Hitchcock MG, et al. Cutaneous lupus erythematosus simulating squamous neoplasia: the clinicopathologic conundrum and histopathologic pitfalls. J Am Acad Dermatol. 2007 Jun;56(6):1013-20. Resumo

58. Perniciaro C, Randle HW, Perry HO. Hypertrophic discoid lupus erythematosus resembling squamous cell carcinoma. Dermatol Surg. 1995 Mar;21(3):255-7. Resumo

59. Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Verrucous lesion in patients with discoid lupus erythematosus. Clinical, histopathological and immunofluorescence studies. Br J Dermatol. 1978 May;98(5):507-20. Resumo

60. Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002 Jul;20(3):373-85. Resumo

61. Reid C. Drug treatment of cutaneous lupus. Am J Clin Dermatol. 2000 Nov-Dec;1(6):375-9. Resumo

62. Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus. 1997 Feb 1;6(2):96-104. Resumo

63. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am. 1989 Sep;73(5):1073-90. Resumo

64. Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992 Jan;128(1):39-42. Resumo

65. Christophers E, Kiene P. Guttate and plaque psoriasis. Dermatol Clin. 1995 Oct;13(4):751-6. Resumo

66. Mehregan DR, Hamzavi F, Brown K. Large cell acanthoma. Int J Dermatol. 2003 Jan;42(1):36-9. Resumo

67. Roewert HJ, Ackerman AB. Large-cell acanthoma is a solar lentigo. Am J Dermatopathol. 1992 Apr;14(2):122-32. Resumo

68. Sanchez Yus E, del Rio E, Requena L. Large-cell acanthoma is a distinctive condition. Am J Dermatopathol. 1992 Apr;14(2):140-7. Resumo

69. Rahbari H, Pinkus H. Large cell acanthoma. One of the actinic keratoses. Arch Dermatol. 1978 Jan;114(1):49-52. Resumo

70. Sanchez Yus E, de Diego V, Urrutia S. Large cell acanthoma. A cytologic variant of Bowen's disease? Am J Dermatopathol. 1988 Jun;10(3):197-208. Resumo

71. Uhlenhake EE, Sangueza OP, Lee AD, et al. Spreading pigmented actinic keratosis: a review. J Am Acad Dermatol. 2010 Sep;63(3):499-506. Resumo

72. Yantsos VA, Conrad N, Zabawski E, et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999 Mar;18(1):3-14. Resumo

73. Carag HR, Prieto VG, Yballe LS, et al. Utility of step sections: demonstration of additional pathological findings in biopsy samples initially diagnosed as actinic keratosis. Arch Dermatol. 2000 Apr;136(4):471-5.Texto completo  Resumo

74. Scurry J. Grading of actinic keratoses. J Am Acad Dermatol. 2001 Jun;44(6):1052-3. Resumo

75. European Dermatology Forum. Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. 2015 [internet publication].Texto completo

76. Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004415.Texto completo  Resumo

77. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000 Aug;26(8):728-32 Resumo

78. Touma D, Yaar M, Whitehead S, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004 Jan;140(1):33-40.Texto completo  Resumo

79. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002 Aug;47(2):258-62. Resumo

80. Braathen LR, Szeimies RM, Basset-Seguin N, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007 Jan;56(1):125-43. Resumo

81. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004 Jan;140(1):41-6.Texto completo  Resumo

82. Fayter D, Corbett M, Heirs M, et al. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess. 2010 Jul;14(37):1-288. Resumo

83. Tierney E, Barker A, Ahdout J, et al. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009 May;35(5):725-46. Resumo

84. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009 May;160(5):1066-74. Resumo

85. Askew DA, Mickan SM, Soyer HP, et al. Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials. Int J Dermatol. 2009 May;48(5):453-63. Resumo

86. Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat. 2010 Sep;21(5):267-71. Resumo

87. Dummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003 Nov;149 Suppl 66:57-8. Resumo

88. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002 Nov;138(11):1498-502. Resumo

89. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol. 2002 Oct;47(4):571-7. Resumo

90. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714-21. Resumo

91. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004 Oct;51(4):547-55. Resumo

92. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and topical fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005 Oct;9(5):209-14. Resumo

93. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006 Sep;55(3):537-8. Resumo

94. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006 Jun;126(6):1251-5.Texto completo  Resumo

95. Stockfleth E, Christophers E, Benninghoff B, et al. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol. 2004 Dec;140(12):1542. Resumo

96. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):582-90. Resumo

97. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):573-81. Resumo

98. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 2002 Jul;76(1):73-80. Resumo

99. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001 Jan 1;61(1):303-8.Texto completo  Resumo

100. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998 May;19(5):723-9.Texto completo  Resumo

101. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol. 2006 Feb;5(2):167-73. Resumo

102. Pflugfelder A, Welter AK, Leiter U, et al; German Dermatologic Cooperative Oncology Group. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):48-53. Resumo

103. Nelson C, Rigel D. Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: one-year evaluation. J Clin Aesth Dermatol. 2009 Jul;2(7):20-5.Texto completo

104. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006 Feb;5(2):156-9. Resumo

105. Iraji F, Siadat AH, Asilian A, et al. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf. 2008 Mar;7(2):167-72. Resumo

106. Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol. 2012 May-Jun;22(3):370-4. Resumo

107. European Medicines Agency. EMA suspends Picato as a precaution while review of skin cancer risk continues. January 2020 [internet publication].Texto completo

108. Fewkes JL, Cheney ML, Pollack SV. Dermabrasion. In: Illustrated atlas of cutaneous surgery. 1st ed. Philadelphia, PA: J.B. Lippincott Company; 1992:26.1-26.11.

109. Esser, AC, Harmon CB. Complications of dermabrasion. In: Nouri K, ed. Complications of dermatologic surgery. Philadelphia, PA: Mosby Elsevier; 2008:207-17.

110. Harmon CB. Dermabrasion. Dermatol Clin. 2001 Jul;19(3):439-42, viii. Resumo

111. Orenstein A, Goldan O, Weissman O, et al. A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J Cosmet Laser Ther. 2007 Mar;9(1):23-5. Resumo

112. Peterson SR, Goldberg LH. New and emerging treatments for nonmelanomas and actinic keratoses. J Drugs Dermatol. 2003 Aug;2(4):429-32. Resumo

113. McMahon AP. More surprises in the Hedgehog signaling pathway. Cell. 2000 Jan 21;100(2):185-8. Resumo

114. Miller SJ, Yu TC. Cyclopamine as a potential therapeutic agent for treatment of tumors related to hedgehog pathway mutations. Dermatol Surg. 2002 Feb;28(2):187. Resumo

115. Tas S, Avci O. Rapid clearance of psoriatic skin lesions induced by topical cyclopamine. A preliminary proof of concept study. Dermatology. 2004;209(2):126-31. Resumo

116. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996 Jun 14;272(5268):1668-71. Resumo

117. Surjana D, Halliday GM, Martin AJ, et al. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol. 2012 May;132(5):1497-500. Resumo

118. Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011 Nov;165(5):1101-8. Resumo

119. Ghuznavi N, Nocera NF, Guajardo AR, et al. Emerging medical treatments for actinic keratoses, squamous cell carcinoma and basal cell carcinoma. Clin Investig. 2012 Sep;2:909-21.

120. All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat assessment report (Limited submission), Advice no. 1012: Fluorouracil/salicylic acid (Actikerall®). March 2012 [internet publication].Texto completo

121. Dohil MA. Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis. J Drugs Dermatol. 2016 Oct 1;15(10):1218-24. Resumo

122. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988 Apr 9;1(8589):795-7. Resumo

123. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4. Resumo

124. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986 Dec;115(6):649-55. Resumo

125. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratoses. J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):392-4. Resumo

126. Ehrig T, Cockerell C, Piacquadio D, et al. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006 Oct;32(10):1261-5. Resumo

127. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979 Dec 8;2(6203):1461-6.Texto completo  Resumo

128. Blohme I, Larko O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol. 1990;70(6):491-4. Resumo

129. Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet. 1971 Dec 11;2(7737):1282-3. Resumo

130. Hardie IR, Strong RW, Hartley LC, et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery. 1980 Feb;87(2):177-83. Resumo

131. Bouwes Bavinck JN, Hardie DR, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996 Mar 15;61(5):715-21. Resumo

132. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):25-8. Resumo

133. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982 Nov;7(5):631-2. Resumo

134. Thai KE, Fergin P, Freeman M, et al A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004 Sep;43(9):687-92. Resumo

135. Zouboulis CC, Rohrs H. Cryosurgical treatment of actinic keratoses and evidence-based review. Hautarzt. 2005 Apr;56(4):353-8. Resumo

136. Stockfleth E, Kerl H; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006 Nov-Dec;16(6):599-606. Resumo

137. Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol. 2007 Jan;156(1):11-21. Resumo

138. Montgomery H, Dorffel J. Verruca senilis und keratoma senile. Arch f Dermat u Syphil (Berlin). 1932;166:286-97.

139. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992 Jun;26(6):976-90. Resumo

140. Czarnecki D, Staples M, Mar A, et al. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology. 1994;189(1):52-4. Resumo

141. Lang K, Schulte KW, Ruzicka T, et al. Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. Skin Therapy Lett. 2001 Sep;6(10):1-2, 5. Resumo

142. North P, Zembowicz A, Mihm M, et al. Sun induced skin diseases. Pathol Int. 2004;54:S559-69.

143. Monheit GD. Medium-depth chemical peels. Dermatol Clin. 2001 Jul;19(3):413-25, vii. Resumo

144. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999 Jan;25(1):18-22. Resumo

145. Kligman D, Kligman AM. Salicylic acid peels for the treatment of photoaging. Dermatol Surg. 1998 Mar;24(3):325-8. Resumo

146. Ghersetich I, Teofoll P, Gantcheva M, et al. Chemical peeling: how, when, why? J Eur Acad Dermatol Venereol. 1997 Jan;8(1):1-11.

147. Rubin MG. Salicylic acid peels (nonfacial). In: Rubin MG, ed. Manual of chemical peels. Superficial and medium depth. 1st ed. Philadelphia, PA: J.B. Lippincott Company; 1995:103-9.

148. Dolezal J. Jessner's peels. In: Rubin MG, ed. Manual of chemical peels. Superficial and medium depth. 1st ed. Philadelphia, PA: J.B. Lippincott Company; 1995:79-88.

O uso deste conteúdo está sujeito ao nosso aviso legal